Tue, Sep 16, 2014, 6:50 AM EDT - U.S. Markets open in 2 hrs 40 mins

Recent

% | $
Quotes you view appear here for quick access.

ImmunoCellular Therapeutics, Ltd. Message Board

mrbogus411 43 posts  |  Last Activity: Sep 9, 2014 8:13 PM Member since: Feb 22, 2014
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • mrbogus411 mrbogus411 Sep 9, 2014 8:13 PM Flag

    When you recommended to sell?... LOL...

    I bought double my initial position. I'm sitting happily with my basis now under a buck. 184% PFS means this is moving forward in one fashion or another. Looking at the market, IMUC is one of my safer positions because the data for supporting further development is ALREADY there.

    The market sell off after the June update was an overreaction. This is going to develop, eventually into a PhaseIII, and hopefully beyond. Here's what I think of your recommendation, IMUC is in deep bargain territory, and I'm still buying.

  • I was hoping it would stay flat at $0.90 for two more weeks, until I had some disposable cash to add a little more. But there was some decent volume the last few days that took it up, and more volume today. Now I'm not sure if I should wait for a dip, or just take it at market... I was hoping to top off my position in Sept... before any updates on the meetings with the FDA and EMA. Oy vey...

    I'm so anxious to know what the meeting outcomes are. On one hand the notes about meeting OS endpoints have been stressed, but on the other hand, there's no way a 184% PFS goes overlooked even if it's only for a subgroup. My guess is that IMUC might not get everything they want, but there's going to be something really positive that moves forward.

  • Mr. Gengos said it best. We're in between events, the lull between developmental stages. But their priorities and motivation are solid, and they're committed and confident.

    I like that he said they're going to move forward with 107 for HLA A2, but not give up on the rest. This tells me they have good reason to suspect 107 may show more efficacy in all patients, perhaps in combination therapy. Most exciting was the many leads he presented, from the discussions with the EMA, the FDA, the neurooncology community, and the potential partners who are interested... and that's just for 107. The way things are set up right now, I definitely think anything under $2 is a bargain.

  • Reply to

    Simple Reason for IND/IST Transfer

    by irishtrader52 Aug 7, 2014 9:37 AM
    mrbogus411 mrbogus411 Aug 7, 2014 4:43 PM Flag

    After all the good results from this drug, the anti-imetelstat group is definitely shady. Something's going on with them.

  • Reply to

    Simple Reason for IND/IST Transfer

    by irishtrader52 Aug 7, 2014 9:37 AM
    mrbogus411 mrbogus411 Aug 7, 2014 3:39 PM Flag

    I agree, the FDA couldn't hold out against the "tantamount cures" in the Mayo Clinic study. It's just a matter of time for the Phaseii to commence.

  • Reply to

    My last addition.

    by mrbogus411 Aug 6, 2014 4:06 PM
    mrbogus411 mrbogus411 Aug 7, 2014 3:38 PM Flag

    Lots of shorts are trolling this board, they look pretty desperate now. Patients on this drug were practically cured, it's pretty clear where this is going. And remember how 17% of float is short? Sweating much? Hey shorts, bring it down some more, I'll go ahead and pick up some more cheap shares.

  • Reply to

    My last addition.

    by mrbogus411 Aug 6, 2014 4:06 PM
    mrbogus411 mrbogus411 Aug 6, 2014 4:14 PM Flag

    How much are you down from shorting this?

  • mrbogus411 by mrbogus411 Aug 6, 2014 4:06 PM Flag

    Is anyone else adding? I couldn't resist one more foray at $2.43, but I think this is the last add for me. My portfolio is leaning a bit heavy on biotech because of Gern. It seems like they're going to have something significant to share on Monday, like info on the Phaseii study.

    I forgot who posted it, but I agree that extending the current study can only mean there has been progress, especially since there's mention of the RARS group continuing to get the drug. Plus, with that Yale study that shrunk all those tumors, I feel good about my position.

    And the new short numbers should be out soon, I wouldn't be surprised to see shorts doubling down. With any Phaseii news or other good news on Monday, I think the shorts are going to carry us up a mountain on their broken backs.

  • Reply to

    A BIG QUESTION FOR ME IS....

    by mainecoastlover1 Aug 5, 2014 12:51 PM
    mrbogus411 mrbogus411 Aug 5, 2014 1:10 PM Flag

    Maybe he disagreed with Geron taking over the Mayo trial. So he said he'll resign if they do it, and they went ahead with it, and he resigned for "other opportunities." Which they did not list. Plus, Geron isn't the only company in the universe to be making drugs with potential. Maybe he got a job at another company with just as much potential, and they're paying him more.

  • Reply to

    Golf Paul go short tomorrow..

    by jlwbigd Jul 29, 2014 5:09 PM
    mrbogus411 mrbogus411 Jul 29, 2014 9:20 PM Flag

    Why is 107 dead? PFS was 184% over control for HLA A2. Avastin was given accelerated approval on the basis of PFS, and it doesn't extend OS. Because of the stark PFS advantage for the subgroup, I think 107 can be another second-line treatment.

  • Reply to

    webcast

    by twicesilent23 Jul 29, 2014 4:33 PM
    mrbogus411 mrbogus411 Jul 29, 2014 4:36 PM Flag

    Spoke too soon. Just starting.

  • Reply to

    webcast

    by twicesilent23 Jul 29, 2014 4:33 PM
    mrbogus411 mrbogus411 Jul 29, 2014 4:35 PM Flag

    Same here. Still waiting.

  • I have a very modest position here. But I don't get where this company is taking this. What's the next development that justifies more than half a trillion market cap? What I'm scared of is market saturation for personal electronic devices, and then what? It seems just like the cellular telecoms, except once they saturated the market with phones, their next sell was data and speed. Are apps going to continue the 16x P/E? And it's not like the competition is just sitting on their hands, either. The competition... is competitive. So just wondering if any of you have insights into what this company is going to do.

  • In my experience, this is what accumulation looks like. Some others said this stock was being manipulated, and now I agree 100%. The recent sell off started with bigger volume, and bigger drops. Yesterday's volume didn't even hit 2mil, and the price trailed off in the 2.30s. Sure the catalyst was Yellen's comments on biotech, but the manipulators took an opportunistic bite.

    Look at today's volume, it's already above 1mil, and it's not even 2hrs into trading. The manipulators dropped the price until no one wanted to sell, and now they're buying back at a lower price. That's what accumulation looks like.

  • Reply to

    ASTERIAS BIOTHERAPEU (ASTYV)

    by beavertail_splash Jul 28, 2014 5:27 PM
    mrbogus411 mrbogus411 Jul 28, 2014 5:35 PM Flag

    There were only 4,400 shares traded.

  • Where does AAPL go from here? I have a hard time seeing innovation in consumer electronics as a way forward for the long term. What's the goal here, to basically do what Sony does, except the American version? Maybe make a game console? As an investor, I just don't see what the next step is.

  • Bargain.

  • mrbogus411 by mrbogus411 Jul 26, 2014 8:58 PM Flag

    A meteor that crashed into a satellite,
    which crashed into a plane,
    which crashed into a truck,
    which crashed into a bunch of cars,
    which crashed into a train,

    and the train spilled toxic waste over a farm,
    and then seeped into the Ogallala Aquifer,
    poisoning all of America's fertile plains,

    which caused a massive, global food shortage,
    which caused World War 3,
    which caused a nuclear winter,
    which caused humans to burrow underground,

    where they competed for limited space and resources,
    where World War 4 occurred,
    where the last nuclear weapons were detonated,

    which ignited the Earth's core,
    which burned away Earth's mantle,
    which ended all life on Earth.

    Except unlike the meteor, Yahoo does this on purpose.

  • The drug will save so many lives, and yet there will be a rash of suicides across the globe when the shorts are unable to cover. Looks like 25ish mil was the top of the short curve, since several attempts to break it failed, and any where near these upper limits means the shorts are in danger. Shorts got it wrong on this one. Their greed took over, and they shorted below $2, and then the Mayo Clinic hold was lifted, and now so many shorts are underwater. No doubt some underwater shorts doubled down. Every time this stock makes dips without any developments, more shorts will be drawn in and trapped, like bugs to the bug zapper.

  • Reply to

    Look at the bids for ASTYV

    by mrbogus411 Jul 24, 2014 11:55 AM
    mrbogus411 mrbogus411 Jul 24, 2014 12:35 PM Flag

    Not series A. The only ones holding series A is Geron shareholders.

IMUC
0.9198-0.0091(-0.98%)Sep 15 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Avanir Pharmaceuticals, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT
21Vianet Group, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT